Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | TTR | P02766 | 1/20 | 0.38 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5173975 | 0.91 | KDM4E (0.45) | KDM4EKMT2ATSHRL3MBTL1ALDH1A1 | |
| SCHEMBL15218757 | 0.84 | SMN1; SMN2 (0.47) | KDM4EKMT2ATSHRALDH1A1MEN1 | |
| SCHEMBL17893778 | 0.82 | L3MBTL1 (0.53) | KDM4EKMT2AL3MBTL1RAB9ANPC1 | |
| SCHEMBL29521181 | 0.82 | MAPT (0.50) | KDM4EKMT2AL3MBTL1RAB9ANPC1 | |
| SCHEMBL842107 | 0.82 | MAPT (0.50) | KDM4EKMT2AL3MBTL1RAB9ANPC1 | |
| SCHEMBL23759950 | 0.81 | CYP3A4 (0.37) | KDM4EKMT2ATSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL89387 | 0.81 | TSHR (0.62) | KDM4EKMT2ATSHRL3MBTL1ALDH1A1 | |
| SCHEMBL20576387 | 0.81 | KDM4E (0.43) | KDM4EKMT2AL3MBTL1ALDH1A1MEN1 | |
| SCHEMBL1911365 | 0.81 | KDM4E (0.43) | KDM4EKMT2ATSHRL3MBTL1ALDH1A1 | |
| SCHEMBL90673 | 0.81 | KDM4E (0.51) | KDM4EKMT2AL3MBTL1ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020239656-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF HEPATITIS B | GALAPAGOS NV (BE) | 2020-12-03 | — | — | WO | disclosed |
| WO-2020239656-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF HEPATITIS B | GALAPAGOS NV (BE) | 2020-12-03 | — | — | WO | disclosed |
| WO-2019100735-A1 | FUSED TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2019-05-31 | — | — | WO | disclosed |
| US-20120022100-A1 | ORGANIC COMPOUNDS | MAIBAUM JUERGEN KLAUS (DE) | 2012-01-26 | — | — | US | disclosed |
| US-20090076062-A1 | Organic Compounds | MAIBAUM JUERGEN KLAUS | 2009-03-19 | — | — | US | disclosed |
| EP-1958666-A1 | Heterocyclic-substituted alkanamides as therapeutic compounds | Speedel Experimenta AG (CH) | 2008-08-20 | — | — | EP | disclosed |
| US-20080176947-A1 | Heterocyclic-Substituted Alkanamides Useful as Renin Inhibitors | NOVARTIS AG (CH) | 2008-07-24 | — | — | US | disclosed |
| CN-101171230-A | Heterocyclic-substituted alkanamides useful as renin inhibitors | SPEEDEL EXPERIMENTA AG (CH) | 2008-04-30 | — | — | CN | disclosed |
| EP-1856032-A1 | HETEROCYCLIC-SUBSTITUTED ALKANAMIDES USEFUL AS RENIN INHIBITORS | Speedel Experimenta AG (CH) | 2007-11-21 | — | — | EP | disclosed |
| WO-2006095020-A1 | HETEROCYCLIC-SUBSTITUTED ALKANAMIDES USEFUL AS RENIN INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2006-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022100-A1 | ORGANIC COMPOUNDS | AGTR1, AGTR2, REN | KDM4E 4349/4885KMT2A 4294/4885TSHR 2323/4885 |
| US-20080176947-A1 | Heterocyclic-Substituted Alkanamides Useful as Renin Inhibitors | REN, ACE, AGTR1 | KDM4E 1612/4885KMT2A 2552/4885TSHR 1434/4885 |
| US-20090076062-A1 | Organic Compounds | AGTR1, AGTR2, REN | KDM4E 4349/4885KMT2A 4294/4885TSHR 2323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.